Saturna Capital CORP Has $76.31 Million Stake in Johnson & Johnson (JNJ)
Saturna Capital CORP boosted its position in Johnson & Johnson (NYSE:JNJ) by 0.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 612,711 shares of the company’s stock after buying an additional 85 shares during the period. Johnson & Johnson comprises approximately 2.6% of Saturna Capital CORP’s investment portfolio, making the stock its 3rd largest position. Saturna Capital CORP’s holdings in Johnson & Johnson were worth $76,313,000 at the end of the most recent reporting period.
Several other large investors have also recently bought and sold shares of the company. State Street Corp increased its stake in Johnson & Johnson by 4.3% in the first quarter. State Street Corp now owns 160,223,321 shares of the company’s stock worth $19,955,806,000 after buying an additional 6,656,371 shares in the last quarter. Norges Bank purchased a new stake in Johnson & Johnson during the fourth quarter worth approximately $3,220,322,000. Schwab Charles Investment Management Inc. increased its stake in Johnson & Johnson by 1.8% in the first quarter. Schwab Charles Investment Management Inc. now owns 11,150,339 shares of the company’s stock worth $1,388,775,000 after buying an additional 201,703 shares in the last quarter. Fisher Asset Management LLC increased its stake in Johnson & Johnson by 1.2% in the first quarter. Fisher Asset Management LLC now owns 11,093,898 shares of the company’s stock worth $1,381,745,000 after buying an additional 136,764 shares in the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. increased its stake in Johnson & Johnson by 0.5% in the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 7,948,942 shares of the company’s stock worth $990,041,000 after buying an additional 42,144 shares in the last quarter. Institutional investors own 66.06% of the company’s stock.
Shares of Johnson & Johnson (NYSE:JNJ) traded up 0.01% during midday trading on Friday, hitting $133.10. The stock had a trading volume of 4,270,571 shares. Johnson & Johnson has a 52-week low of $109.32 and a 52-week high of $137.08. The firm has a market cap of $357.24 billion, a price-to-earnings ratio of 22.52 and a beta of 0.78. The firm’s 50 day moving average price is $133.09 and its 200 day moving average price is $126.30.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, July 18th. The company reported $1.83 earnings per share for the quarter, topping analysts’ consensus estimates of $1.79 by $0.04. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The business had revenue of $18.84 billion for the quarter, compared to analyst estimates of $18.94 billion. During the same quarter in the prior year, the company earned $1.74 earnings per share. The company’s revenue was up 1.9% on a year-over-year basis. On average, equities research analysts expect that Johnson & Johnson will post $7.18 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 12th. Stockholders of record on Tuesday, August 29th will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.52%. The ex-dividend date of this dividend is Friday, August 25th. Johnson & Johnson’s dividend payout ratio is currently 56.76%.
JNJ has been the topic of a number of research analyst reports. BidaskClub upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 17th. Jefferies Group LLC reiterated a “hold” rating and issued a $135.00 target price (down from $140.00) on shares of Johnson & Johnson in a research report on Sunday, May 14th. Royal Bank Of Canada reiterated a “buy” rating and issued a $128.00 target price on shares of Johnson & Johnson in a research report on Thursday, June 15th. Atlantic Securities downgraded Johnson & Johnson from a “neutral” rating to an “underweight” rating and set a $113.00 target price on the stock. in a research report on Friday, July 21st. Finally, Barclays PLC reiterated an “equal weight” rating and issued a $130.00 target price (up from $125.00) on shares of Johnson & Johnson in a research report on Monday, April 17th. Three research analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $133.72.
In other news, VP Dominic J. Caruso sold 82,591 shares of the company’s stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the sale, the vice president now owns 226,693 shares of the company’s stock, valued at $30,993,466.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Paulus Stoffels sold 102,692 shares of the company’s stock in a transaction on Monday, July 24th. The stock was sold at an average price of $133.14, for a total value of $13,672,412.88. Following the sale, the vice president now directly owns 230,342 shares in the company, valued at approximately $30,667,733.88. The disclosure for this sale can be found here. 0.19% of the stock is currently owned by corporate insiders.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.